Summary
- iTeos Therapeutics has filed to raise $151 million from an IPO of its common stock.
- The firm is developing treatments for solid tumors and other high prevalence cancer conditions.
- ITOS is pursuing extremely large markets and the IPO appears reasonably valued, so it is worth considering.
- Looking for more stock ideas like this one? Get them exclusively at IPO Edge. Get started today ยป
Quick Take
iTeos Therapeutics (ITOS) intends to raise $151 million from the sale of its common stock in an IPO, according to an amended registration statement.
ITOS is pursuing treatments for highly prevalent cancer conditions, such as solid tumors, and the IPO appears reasonably valued.
Company & Technology
Cambridge, Massachusetts-based iTeos was founded to develop treatments for a wide range of solid tumor, blood and other cancers that enhance the body's immune system to improve cancer targeting effects.
Management is headed by Chief Executive Officer Mr. Michel Detheux, Ph.D, who has been with the firm since the company's inception and was previously a director at Ludwig Cancer Research and held several roles at Ogeda.
Below is a brief overview video of iTeos:
